{"id":2902,"date":"2023-12-12T00:30:42","date_gmt":"2023-12-11T23:30:42","guid":{"rendered":"https:\/\/invivo.partners\/?p=2902"},"modified":"2023-12-12T11:01:58","modified_gmt":"2023-12-12T10:01:58","slug":"invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/","title":{"rendered":"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d’enginyeria in vivo."},"content":{"rendered":"

\"\"<\/p>\n

Invivo Ventures anuncia avui una inversi\u00f3 de 2 milions d’euros a EsoBiotec, una empresa pionera en biotecnologia centrada en el desenvolupament de ter\u00e0pies cel\u00b7lulars in vivo per al tractament del c\u00e0ncer. Aquesta inversi\u00f3 \u00e9s part d’una ronda de finan\u00e7ament S\u00e8rie A, que s’espera que s’acabi el 2024. Segueix una ronda de finan\u00e7ament inicial tancada el 2021, amb contribucions d’inversors destacats com UCB Ventures, Thuja Capital, Sambrinvest i Wallonie Entreprendre (anteriorment SRIW).<\/p>\n

EsoBiotec est\u00e0 a l’avantguarda de la innovaci\u00f3 en ter\u00e0pia contra el c\u00e0ncer, especialitzant-se en l’enginyeria in vivo de limf\u00f2cits T i altres c\u00e8l\u00b7lules del sistema immunol\u00f2gic. Per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer, EsoBiotec est\u00e0 desenvolupant una tecnologia sofisticada per dur a terme la \u00abreenginyeria gen\u00e8tica\u00bb de limf\u00f2cits T dins del propi cos del pacient en lloc d’en un laboratori.<\/p>\n

EsoBiotec utilitza vectors virals per a aquest proc\u00e9s de reenginyeria. Aquest enfocament nou cerca superar les limitacions de les ter\u00e0pies cel\u00b7lulars ex vivo tradicionals, que estan associades amb alts costos i involucren processos de fabricaci\u00f3 complexos i llargs que requereixen que els pacients esperin setmanes, de vegades mesos, abans d’accedir a una ter\u00e0pia. El producte principal de l’empresa aprofita l’avan\u00e7ada plataforma d’EsoBiotec per validar aquest nou enfocament tecnol\u00f2gic utilitzant un antigen cl\u00ednicament provat. Alhora, EsoBiotec est\u00e0 expandint la seva pipeline per cobrir altres tipus de c\u00e8l\u00b7lules immunol\u00f2giques i ampliar el seu abast a tumors s\u00f2lids.<\/p>\n

Jean-Pierre Latere, CEO, explica: \u00abEsoBiotec t\u00e9 com a objectiu transformar l’atenci\u00f3 oncol\u00f2gica basada en ter\u00e0pies cel\u00b7lulars com els limf\u00f2cits T modificats. Les nostres dades precl\u00ednices confirmen el potencial dels nostres vectors per crear noves opcions terap\u00e8utiques off-the-shelf. Ens estem preparant per portar la nostra tecnologia als pacients en els propers dos anys, gr\u00e0cies al nostre enfocament d’enginyeria cel\u00b7lular in vivo, milers de pacients a tot el m\u00f3n haurien de poder tenir acc\u00e9s i beneficiar-se d’una ter\u00e0pia altament innovadora en els propers anys. el suport i la confian\u00e7a d’Invivo Partners mentre ens preparem per tancar la nostra S\u00e8rie A en els propers mesos\u201d.<\/p>\n

Aquesta inversi\u00f3 estrat\u00e8gica d\u00b4Invivo Ventures subratlla una visi\u00f3 compartida d\u00b4un futur en qu\u00e8 les ter\u00e0pies avan\u00e7ades contra el c\u00e0ncer siguin m\u00e9s efectives, accessibles i capaces d\u00b4abordar alguns dels aspectes m\u00e9s desafiadors de l\u00b4atenci\u00f3 oncol\u00f2gica.<\/p>\n

Laura Rodr\u00edguez, Principal a Invivo, s’unir\u00e0 al Consell i va comentar sobre la inversi\u00f3, declarant: \u00abA Invivo, estem compromesos a fomentar la innovaci\u00f3 en ter\u00e0pies avan\u00e7ades, i l’avan\u00e7ada plataforma d’enginyeria in vivo d’EsoBiotec s’alinea perfectament amb la nostra visi\u00f3. Aquesta plataforma no \u00e9s nom\u00e9s un salt en innovaci\u00f3, t\u00e9 el potencial de revolucionar les ter\u00e0pies cel\u00b7lulars contra el c\u00e0ncer, ens sentim orgullosos d’unir forces amb UCB Ventures, Thuja Capital, Sambrinvest i WE (Wallonie Entreprendre) en aquest sindicat d’inversi\u00f3. seguim amb expectativa el desenvolupament de la tecnologia d’EsoBiotec en el tractament del c\u00e0ncer, amb l’esperan\u00e7a d’assolir \u00e8xits en aquest camp innovador\u201d.<\/p>\n

Sobre EsoBiotec<\/strong>
\nEsoBiotec \u00e9s una empresa belga de biotecnologia centrada en el desenvolupament de ter\u00e0pies innovadores per combatre el c\u00e0ncer. EsoBiotec va ser fundada el 2020 amb la missi\u00f3 de potenciar el cos hum\u00e0 per combatre el c\u00e0ncer mitjan\u00e7ant l’enginyeria cel\u00b7lular \u201cin vivo\u201d (que t\u00e9 lloc dins del cos) per als pacients. El seu objectiu \u00e9s desenvolupar ter\u00e0pies llestes per utilitzar, rendibles, per proporcionar tractaments de ter\u00e0pia cel\u00b7lular d\u00faltima generaci\u00f3 i maximitzar lacc\u00e9s a latenci\u00f3 oncol\u00f2gica que canvia vides. El seu enfocament disruptiu t\u00e9 el potencial de transformar l\u02bbest\u00e0ndard actual de les ter\u00e0pies cel\u00b7lulars per al tractament del c\u00e0ncer. M\u00e9s informaci\u00f3: esobiotec.com<\/a> i LinkedIn<\/a>.<\/p>\n

Sobre Invivo Partners<\/strong>
\nInvivo Partners \u00e9s una signatura de capital de risc espanyola fundada pel Dr. Luis Pareras i Albert Ferrer, que gestiona Invivo Ventures FCR, un fons de capital de risc que inverteix en empreses de ci\u00e8ncies de la vida en una etapa primerenca. Invivo Ventures FCR t\u00e9 la majoria d’inversors privats amb el suport de diversos inversors institucionals com el Fons Europeu d’Inversions (EIF), el Fond-ICO Global, l’Institut Catal\u00e0 de Finances, l’Institut Valenci\u00e0 de Finances i l’Ajuntament de Barcelona. M\u00e9s informaci\u00f3: invivo.partners<\/a>.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Invivo Ventures anuncia avui una inversi\u00f3 de 2 milions d’euros a EsoBiotec, una empresa pionera en biotecnologia centrada en el desenvolupament de ter\u00e0pies cel\u00b7lulars in vivo per al tractament del c\u00e0ncer. Aquesta inversi\u00f3 \u00e9s part d’una ronda de finan\u00e7ament S\u00e8rie A, que s’espera que s’acabi el 2024. Segueix una ronda de finan\u00e7ament inicial tancada el<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[],"class_list":["post-2902","post","type-post","status-publish","format-standard","hentry","category-noticias-ca"],"acf":[],"yoast_head":"\nInvivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d'enginyeria in vivo. - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d'enginyeria in vivo. - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Invivo Ventures anuncia avui una inversi\u00f3 de 2 milions d’euros a EsoBiotec, una empresa pionera en biotecnologia centrada en el desenvolupament de ter\u00e0pies cel\u00b7lulars in vivo per al tractament del c\u00e0ncer. Aquesta inversi\u00f3 \u00e9s part d’una ronda de finan\u00e7ament S\u00e8rie A, que s’espera que s’acabi el 2024. Segueix una ronda de finan\u00e7ament inicial tancada el\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-11T23:30:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-12T10:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/invivo.partners\/wp-content\/uploads\/2023\/12\/esobiotec-300x158.jpg\" \/>\n<meta name=\"author\" content=\"Bego\u00f1a Aguirre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bego\u00f1a Aguirre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\"},\"author\":{\"name\":\"Bego\u00f1a Aguirre\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\"},\"headline\":\"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d’enginyeria in vivo.\",\"datePublished\":\"2023-12-11T23:30:42+00:00\",\"dateModified\":\"2023-12-12T10:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\"},\"wordCount\":788,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\",\"name\":\"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d'enginyeria in vivo. - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2023-12-11T23:30:42+00:00\",\"dateModified\":\"2023-12-12T10:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d’enginyeria in vivo.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\",\"name\":\"Bego\u00f1a Aguirre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"caption\":\"Bego\u00f1a Aguirre\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/bego\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d'enginyeria in vivo. - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/","og_locale":"ca_ES","og_type":"article","og_title":"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d'enginyeria in vivo. - Invivo Partners","og_description":"Invivo Ventures anuncia avui una inversi\u00f3 de 2 milions d’euros a EsoBiotec, una empresa pionera en biotecnologia centrada en el desenvolupament de ter\u00e0pies cel\u00b7lulars in vivo per al tractament del c\u00e0ncer. Aquesta inversi\u00f3 \u00e9s part d’una ronda de finan\u00e7ament S\u00e8rie A, que s’espera que s’acabi el 2024. Segueix una ronda de finan\u00e7ament inicial tancada el","og_url":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/","og_site_name":"Invivo Partners","article_published_time":"2023-12-11T23:30:42+00:00","article_modified_time":"2023-12-12T10:01:58+00:00","og_image":[{"url":"http:\/\/invivo.partners\/wp-content\/uploads\/2023\/12\/esobiotec-300x158.jpg"}],"author":"Bego\u00f1a Aguirre","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Bego\u00f1a Aguirre","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/"},"author":{"name":"Bego\u00f1a Aguirre","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee"},"headline":"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d’enginyeria in vivo.","datePublished":"2023-12-11T23:30:42+00:00","dateModified":"2023-12-12T10:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/"},"wordCount":788,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/","url":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/","name":"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d'enginyeria in vivo. - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2023-12-11T23:30:42+00:00","dateModified":"2023-12-12T10:01:58+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2023\/12\/12\/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Invivo Ventures inverteix a EsoBiotec per revolucionar la ter\u00e0pia cel\u00b7lular contra el c\u00e0ncer amb una avan\u00e7ada plataforma d’enginyeria in vivo."}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee","name":"Bego\u00f1a Aguirre","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","caption":"Bego\u00f1a Aguirre"},"url":"https:\/\/invivo.partners\/ca\/author\/bego\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/2902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=2902"}],"version-history":[{"count":5,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/2902\/revisions"}],"predecessor-version":[{"id":2914,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/2902\/revisions\/2914"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=2902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=2902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=2902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}